<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30072097</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>01</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1090-2104</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>503</Volume>                    <Issue>3</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Biochemical and biophysical research communications</Title>                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>            </Journal>            <ArticleTitle>Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.</ArticleTitle>            <Pagination>                <MedlinePgn>1605-1609</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(18)31584-5</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2018.07.088</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Owing to the absence of any targeted therapies, triple negative breast cancer (TNBC), which accounts for approximately 15% of all breast cancers, typically have a poorer outcome. In an attempt to find out the TNBCs' microenvironment, we ran into the endogenous expression of a newly discovered cytokine known as Interleukin (IL)-22.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Thirty TNBC patients were recruited and the levels of IL-22 producing (Th22) cells in tumor, paratumor and normal breast tissues were measured. Then we studied the role and mechanism of IL-22 in migration and paclitaxel resistance in TNBC cells MDA-MB 468 and MDA-MB 231.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of Th22 cells were gradually increased in normal, paratumor and tumor tissues. In vitro, IL-22 promotes TNBC cells migration and induces paclitaxel resistance. Importantly, IL-22 exposure of TNBC cells resulted in JAK-STAT3/MAPKs/AKT signaling pathways activated.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IL-22 may play an accelerating role in the development of TNBC and may open a new therapeutic approach for TNBC.</AbstractText>                <CopyrightInformation>Copyright Â© 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Shuqian</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, 310003, China; Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, 310003, China. Electronic address: frog8433@163.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yao</LastName>                    <ForeName>Yinan</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Respiratory Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China. Electronic address: yaoyinanwangyujia@163.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yao</LastName>                    <ForeName>Minya</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, 310003, China; Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, 310003, China. Electronic address: yminya@163.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fu</LastName>                    <ForeName>Peifen</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, 310003, China. Electronic address: fupeifen@hotmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Weilin</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China. Electronic address: wam@zju.edu.cn.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>23</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>            <NlmUniqueID>0372516</NlmUniqueID>            <ISSNLinking>0006-291X</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Interleukin-22 (IL-22)</Keyword>            <Keyword MajorTopicYN="N">Target therapy</Keyword>            <Keyword MajorTopicYN="N">Triple negative breast cancer (TNBC)</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30072097</ArticleId>            <ArticleId IdType="pii">S0006-291X(18)31584-5</ArticleId>            <ArticleId IdType="doi">10.1016/j.bbrc.2018.07.088</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>